Assignee
TEVA PHARMACEUTICALS AUSTRALIA PTY LTD
AU·14 granted patents·7 pending applications·53 citations·filing 2013–2025
Top patents by PatentIndex Score
21 records- 0191US10232041B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Mar 19, 2019·9 cites·21 claims
- 0290US10822422B2Antibodies against TL1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Granted Nov 3, 2020·10 cites·13 claims
- 0390US9636334B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted May 2, 2017·9 cites·20 claims
- 0487US9963515B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted May 8, 2018·5 cites·27 claims
- 0587US9611322B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Granted Apr 4, 2017·6 cites·18 claims
- 0687US2025353919A1Antibodies Against TL1A and Uses ThereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2025·Application pending·0 cites
- 0786US12258401B2Anti-CD47 combination therapyTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2022·Granted Mar 25, 2025·1 cites·21 claims
- 0886US10544199B2Interferon alpha 2B variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2015·Granted Jan 28, 2020·7 cites·20 claims
- 0983US12410256B2Antibodies that specifically bind to TL1a and methods of treating gastrointestinal or lung diseasesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2023·Granted Sep 9, 2025·0 cites·19 claims
- 1083US11319356B2Interferon alpha 2B variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2019·Granted May 3, 2022·2 cites·18 claims
- 1183US10981986B2Fusions of antibodies to CD38 and attenuated interferon alphaTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Apr 20, 2021·2 cites·21 claims
- 1275US11117975B2Anti-CD38 antibodies and fusions to attenuated interferon alpha-2BTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2018·Granted Sep 14, 2021·1 cites·13 claims
- 1373US11618784B2Anti-CD47 combination therapyTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2017·Granted Apr 4, 2023·1 cites·21 claims
- 1471US11253591B2Combination of lenalidomide and polypeptide construct, and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2019·Granted Feb 22, 2022·0 cites·17 claims
- 1569US2022220184A1Interferon alpha 2b variantsTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2022·Application pending·0 cites
- 1668US2021347904A1Antibodies against tl1a and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2020·Application pending·0 cites
- 1764US2014255302A1ANTIBODIES AGAINST TL1a AND USES THEREOFTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
- 1854US8901279B2Humanized antibodies with anti-tumor activityTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2013·Granted Dec 2, 2014·0 cites·27 claims
- 1954US2016367695A1Polypeptide constructs and uses thereofTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 2047US2016264661A1Anti-il-12/il-23 antibodiesTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2016·Application pending·0 cites
- 2142US2014286957A1ANTIBODIES TO CD1dTEVA PHARMACEUTICALS AUSTRALIA PTY LTD·Filed 2014·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when TEVA PHARMACEUTICALS AUSTRALIA PTY LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →